Your browser doesn't support javascript.
loading
Immunogenic epitope scanning in bacteriolytic enzymes Pal and Cpl-1 and engineering Pal to escape antibody responses.
Harhala, Marek Adam; Gembara, Katarzyna; Rybicka, Izabela; Kazmierczak, Zuzanna Maria; Miernikiewicz, Paulina; Majewska, Joanna Marta; Budziar, Wiktoria; Nasulewicz-Goldeman, Anna; Nelson, Daniel C; Owczarek, Barbara; Dabrowska, Krystyna.
Afiliação
  • Harhala MA; Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
  • Gembara K; Research and Development Centre, Regional Specialist Hospital, Wroclaw, Poland.
  • Rybicka I; Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
  • Kazmierczak ZM; Research and Development Centre, Regional Specialist Hospital, Wroclaw, Poland.
  • Miernikiewicz P; Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
  • Majewska JM; Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
  • Budziar W; Research and Development Centre, Regional Specialist Hospital, Wroclaw, Poland.
  • Nasulewicz-Goldeman A; Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
  • Nelson DC; Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
  • Owczarek B; Research and Development Centre, Regional Specialist Hospital, Wroclaw, Poland.
  • Dabrowska K; Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Front Immunol ; 14: 1075774, 2023.
Article em En | MEDLINE | ID: mdl-37781366
ABSTRACT
Bacteriolytic enzymes are promising antibacterial agents, but they can cause a typical immune response in vivo. In this study, we used a targeted modification method for two antibacterial endolysins, Pal and Cpl-1. We identified the key immunogenic amino acids, and designed and tested new, bacteriolytic variants with altered immunogenicity. One new variant of Pal (257-259 MKS → TFG) demonstrated decreased immunogenicity while a similar mutant (257-259 MKS → TFK) demonstrated increased immunogenicity. A third variant (280-282 DKP → GGA) demonstrated significantly increased antibacterial activity and it was not cross-neutralized by antibodies induced by the wild-type enzyme. We propose this variant as a new engineered endolysin with increased antibacterial activity that is capable of escaping cross-neutralization by antibodies induced by wild-type Pal. We show that efficient antibacterial enzymes that avoid cross-neutralization by IgG can be developed by epitope scanning, in silico design, and substitutions of identified key amino acids with a high rate of success. Importantly, this universal approach can be applied to many proteins beyond endolysins and has the potential for design of numerous biological drugs.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antibacterianos / Formação de Anticorpos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antibacterianos / Formação de Anticorpos Idioma: En Ano de publicação: 2023 Tipo de documento: Article